The isoflavone biochanin a inhibits the growth of the intracellular bacteria Chlamydia trachomatis and Chlamydia pneumoniae

Planta Medica ◽  
2012 ◽  
Vol 78 (11) ◽  
Author(s):  
L Pohjala ◽  
H Uvell ◽  
E Hakala ◽  
Å Gylfe ◽  
M Elofsson ◽  
...  
2015 ◽  
Vol 68 (10) ◽  
pp. 609-614 ◽  
Author(s):  
Elina Hakala ◽  
Leena Hanski ◽  
Hanna Uvell ◽  
Teijo Yrjönen ◽  
Heikki Vuorela ◽  
...  

2005 ◽  
Vol 73 (8) ◽  
pp. 4620-4625 ◽  
Author(s):  
Mirja Puolakkainen ◽  
Cho-Chou Kuo ◽  
Lee Ann Campbell

ABSTRACT Several mechanisms for attachment and entry of Chlamydia have been proposed. We previously determined that the major outer membrane protein of Chlamydia trachomatis is glycosylated with a high-mannose oligosaccharide, and a similar structure inhibited the attachment and infectivity of C. trachomatis in epithelial cells. Because insulin-like growth factor 2 (IGF2) was shown to enhance the infectivity of Chlamydia pneumoniae but not C. trachomatis in endothelial cells, a hapten inhibition assay was used to analyze whether the mannose 6-phosphate (M6P)/IGF2 receptor that also binds M6P could be involved in infection of endothelial cells (HMEC-1) by Chlamydia. M6P and mannose 6-phosphate-poly[N-(2-hydroxyethyl)-acrylamide] (M6P-PAA) inhibited the infectivity of C. pneumoniae AR-39, but not C. trachomatis serovar UW5 or L2, while mannan inhibited the growth of C. trachomatis, but not C. pneumoniae. Using metabolically labeled organisms incubated with cells at 4°C (organisms attach but do not enter) or at 37°C (organisms attach and are internalized), M6P-PAA was shown to inhibit attachment and internalization of C. pneumoniae in endothelial cells but did not inhibit attachment or internalization of C. trachomatis serovar E or L2. These findings indicate that C. pneumoniae can utilize the M6P/IGF2 receptor and that the use of this receptor for attachment and entry differs between C. pneumoniae and C. trachomatis.


Molecules ◽  
2020 ◽  
Vol 25 (2) ◽  
pp. 294 ◽  
Author(s):  
Eveliina Taavitsainen ◽  
Maarit Kortesoja ◽  
Tanja Bruun ◽  
Niklas G. Johansson ◽  
Leena Hanski

Antibiotic-tolerant persister bacteria involve frequent treatment failures, relapsing infections and the need for extended antibiotic treatment. The virulence of an intracellular human pathogen C. pneumoniae is tightly linked to its propensity for persistence and means for its chemosensitization are urgently needed. In the current work, persistence of C. pneumoniae clinical isolate CV6 was studied in THP-1 macrophages using quantitative PCR and quantitative culture. A dibenzocyclooctadiene lignan schisandrin reverted C. pneumoniae persistence and promoted productive infection. The concomitant administration of schisandrin and azithromycin resulted in significantly improved bacterial eradication compared to sole azithromycin treatment. In addition, the closely related lignan schisandrin C was superior to azithromycin in eradicating the C. pneumoniae infection from the macrophages. The observed chemosensitization of C. pneumoniae was associated with the suppression of cellular glutathione pools by the lignans, implying to a previously unknown aspect of chlamydia–host interactions. These data indicate that schisandrin lignans induce a phenotypic switch in C. pneumoniae, promoting the productive and antibiotic-susceptible phenotype instead of persistence. By this means, these medicinal plant -derived compounds show potential as adjuvant therapies for intracellular bacteria resuscitation.


2004 ◽  
Vol 48 (5) ◽  
pp. 1885-1886 ◽  
Author(s):  
S. A. Kohlhoff ◽  
P. M. Roblin ◽  
T. Reznik ◽  
S. Hawser ◽  
K. Islam ◽  
...  

ABSTRACT The in vitro activities of iclaprim, a novel dihydrofolate reductase inhibitor, azithromycin, and levofloxacin were tested against 10 strains of Chlamydia trachomatis and 10 isolates of Chlamydia pneumoniae. For C. trachomatis and C. pneumoniae, the iclaprim MIC and minimal bactericidal concentration at which 90% of isolates were inhibited (MIC90 and MBC90) were 0.5 μg/ml, compared to an azithromycin MIC90 and MBC90 of 0.125 μg/ml and levofloxacin MIC90s and MBC90s of 1 μg/ml for C. trachomatis and 0.5 μg/ml for C. pneumoniae.


Sign in / Sign up

Export Citation Format

Share Document